WO2018069863A1 - 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors - Google Patents

1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors Download PDF

Info

Publication number
WO2018069863A1
WO2018069863A1 PCT/IB2017/056320 IB2017056320W WO2018069863A1 WO 2018069863 A1 WO2018069863 A1 WO 2018069863A1 IB 2017056320 W IB2017056320 W IB 2017056320W WO 2018069863 A1 WO2018069863 A1 WO 2018069863A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclobutanecarboxamide
thiazol
yloxy
frans
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2017/056320
Other languages
English (en)
French (fr)
Inventor
David Norman Deaton
Yu Guo
Ashley Paul Hancock
Christie SCHULTE
Barry George Shearer
Emilie Despagnet Smith
Eugene L. Stewart
Stephen Andrew Thomson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JOP/2019/0072A priority Critical patent/JOP20190072A1/ar
Priority to AU2017342156A priority patent/AU2017342156B2/en
Priority to CA3038756A priority patent/CA3038756A1/en
Priority to CN201780075127.1A priority patent/CN110072857A/zh
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to MX2019004320A priority patent/MX2019004320A/es
Priority to CR20190174A priority patent/CR20190174A/es
Priority to EP17797738.6A priority patent/EP3526206A1/en
Priority to US16/341,113 priority patent/US11053234B2/en
Priority to BR112019007609A priority patent/BR112019007609A2/pt
Priority to JP2019520150A priority patent/JP6938628B2/ja
Priority to EA201990904A priority patent/EA201990904A1/ru
Priority to KR1020197013195A priority patent/KR20190072565A/ko
Publication of WO2018069863A1 publication Critical patent/WO2018069863A1/en
Priority to IL265597A priority patent/IL265597A/en
Priority to ZA2019/01848A priority patent/ZA201901848B/en
Priority to CONC2019/0003482A priority patent/CO2019003482A2/es
Priority to PH12019500811A priority patent/PH12019500811A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Definitions

  • the present invention relates to novel compounds, to the use of the compounds as Hematopoietic Prostaglandin D Synthase (H-PGDS) inhibitors, to pharmaceutical compositions comprising the compounds and to the use of the compounds in therapy, especially in the treatment of conditions for which a H-PGDS inhibitor is indicated, such as neurodegenerative diseases and musculoskeletal diseases including Duchenne Muscular Dystrophy, where PGD 2 is considered to play a pathological role, forthe use of a compound in the manufacture of a medicament for the treatment of conditions in which an inhibitor of H-PGDS is indicated, and a method for the treatment or prophylaxis of disorders in which inhibition of H-PGDS is indicated, in a human.
  • H-PGDS Hematopoietic Prostaglandin D Synthase
  • Prostaglandin D2 is a product of arachidonic acid metabolism, and is the major prostanoid mediator synthesised by mast cells in response to stimulation via multiple mechanisms and cellular activation pathways, including allergen-mediated cross- linking of high affinity IgE receptors (Lewis et al. (1982) Prostaglandin D2 generation after activation of rat and human mast cells with anti-lgE. J. Immunol., 129, 1627-1631). Other cells such as dendritic cells, Th2 cells, and epithelial cells also produce PGD2, but at lower levels than mast cells. PGD2 mediates its effects via activation of the specific G- protein coupled receptors DPi (Boie et al.
  • mice CRTH2 a putative member of the leukocyte chemo- attractant receptor family. (Gene, 227, 71-77)) and also acts via the receptor for thromboxane A2 (TXA2), the TP receptor, on target cells.
  • TXA2 thromboxane A2
  • Prostaglandin D synthase is the enzyme responsible for the catalytic isomerase conversion of prostaglandin endoperoxide PGH 2 to PGD 2 .
  • PGD 2 is generated by the action of either H-PGDS (hematopoietic-type or H-type) or L-PGDS or (lipocalin-type or L-type) enzymes (Urade et al., (2000) Prostaglandin D synthase structure and function. Vitamins and hormones, 58, 89-120).
  • H-PGDS activity is dependent on glutathione and plays an important role in the generation of PGD2 by immune and inflammatory cells, including mast cells, antigen-presenting cells (e.g.
  • L-type is glutathione-independent and is primarily located in the central nervous system, genital organs, and heart. These two isoforms of PGDS appear to have distinct catalytic properties, tertiary structure, and cellular and tissue distribution.
  • H-PGDS has also been implicated to play a role not only in allergic disease, but also other diseases such as Duchenne Muscular Dystrophy (Nakagawa et al. (2013) A prostaglandin D2 metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old, Clinica Chimica Acta 423, 10-14) and (Mohri et al. (2009), Inhibition of prostaglandin D synthase suppresses muscular necrosis, Am. J. Pathol. 174, 1735-1744) and (Okinaga et al.
  • H-PGDS has also been implicated to play a role in metabolic diseases such as diabetes and obesity, since PGD 2 is converted to 15-deoxy-A 12 14 PGJ2, a potent ligand for PPARv which is able to drive adipogenesis (Tanaka et al (201 1 ) Mast cells function as an alternative modulator of adipogenesis through 15-deoxy-delta-12, 14-prostaglandin J2. Am. J. Physiol. Cell Physiol. 301 , C1360-C1367).
  • Niacin-induced skin flushing involves release of prostaglandin D2 from mast cells and serotonin from platelets: Evidence from human cells in vitro and an animal model. JPET 327:665-672).
  • the invention is directed to compounds according to Formula I:
  • R, PJ , R2 PA ⁇ ⁇ 1 A , X, and Z are as defined below.
  • a pharmaceutical composition comprising a compound of formula (I) according to the first aspect, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipients.
  • the pharmaceutical composition is for the treatment or prophylaxis of a disorder in which inhibition of H-PGDS is beneficial.
  • the invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof according to the first aspect of the invention for use in therapy.
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a condition forwhich an H-PGDS inhibitor is indicated.
  • This invention also relates to a method of treating Duchenne muscular dystrophy, which comprises administering to a subject in need thereof an effective amount of a H- PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating congenital myotonia, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating muscle injury, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating muscle lacerations, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating chronic muscle strains, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating Myotonic dystrophy type I, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating myotonic dystrophy type II, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating asthma, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating chronic obstructive pulmonary disease, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating rheumatoid arthritis, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating inflammatory bowel disease, which comprises administering to a subject in need thereof an effective amount of a H- PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating osteoarthritis, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating psoriasis, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating a muscle degenerative disorder, which comprises administering to a subject in need thereof an effective amount of a H- PGDS inhibiting compound of Formula (I).
  • This invention also relates to a method of treating muscular dystrophy, which comprises administering to a subject in need thereof an effective amount of a H-PGDS inhibiting compound of Formula (I).
  • Also included in the present invention are methods of co-administering the presently invented H-PGDS inhibiting compounds with further active ingredients.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of Duchenne muscular dystrophy.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of congenital myotonia.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of muscle injury.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of muscle lacerations.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of chronic muscle strains.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of Myotonic dystrophy type I.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of myotonic dystrophy type II.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of asthma.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of chronic obstructive pulmonary disease.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of rheumatoid arthritis.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of inflammatory bowel disease.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of osteoarthritis.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of psoriasis.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of a muscle degenerative disorder.
  • the invention also relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the treatment of muscular dystrophy.
  • the invention provides for the use of a compound of Formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of conditions in which an inhibitor of H-PGDS is indicated.
  • the invention further provides a method for the treatment or prophylaxis of disorders in which inhibition of H-PGDS is indicated, in a human, which comprises administering a human in need thereof a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • Figure 1 depicts the protection and acceleration of functional repai dose response curves of H-PGDS Inhibition using the compound of Example 141 following limb muscle injury in normal mice. DETAILED DESCRIPTION OF THE INVENTION
  • This invention relates to novel compounds of Formula (I):
  • X is selected from: carbon and nitrogen
  • Y is selected from: hydrogen and CH3;
  • Y is absent or CH3;
  • Z is NH or O
  • a is 0 or 1 ;
  • R is selected from: O, NH, CH2 and Ci alkyl substituted by halogen; R is selected from:
  • heteroaryl substituted from 1 to 4 times by R a , bicycloheteroaryl, and
  • R 2 is selected from: O and S;
  • R 3 is selected from:
  • each R a is independently selected from:
  • Cl -6alkyl substituted with from 1 to 5 substituents independently selected from: fluoro, chloro, bromo, iodo, Cl -4alkyloxy, -OH, C1 -4alkyl, oxo, -COOH, -NO2, -NH2 and -CN, cyano,
  • -OCl -6alkyl substituted with from 1 to 5 substituents independently selected from: fluoro, chloro, bromo, iodo, Cl -4alkyloxy, -OH, C1 -4alkyl, oxo, -COOH, -NO2, -NH2 and -CN,
  • each R b is independently selected from:
  • R x is selected from aryl, heteroaryl, cycloalkyi, heterocycloalkyl, -OCl -6alkyl, -OCl -6alkyl substituted with from 1 to 6 substituents independently selected from:
  • each R f is independently selected from: fluoro
  • R is selected from aryl, heteroaryl, cycloalkyi, heterocycloalkyi, Cl -6alkyl, and Cl -6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -OCl -6alkyl, -COOH, -NH2, and -CN, -NR ⁇ R* 3 ,
  • R and R are each independently selected from: aryl, heteroaryl, cycloalkyi, heterocycloalkyi, Cl -6alkyl, and
  • Cl -6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and -CN,
  • each R e is independently selected from: Cl -6alkyl substituted with from 1 to 9 substituents independently selected from:
  • R is selected from aryl, heteroaryl, cycloalkyi, heterocycloalkyi, cyano, Cl -6alkyl, and Cl -6alkyl substituted with from 1 to 6
  • substituents independently selected from: fluoro, oxo, -OH, -COOH, -OCl -5alkyl, -OCl -5alkyl substituted from 1 to 6 times by fluoro,
  • R and R are each independently selected from: aryl, heteroaryl, cycloalkyi, heterocycloalkyi, Cl -6alkyl, and Cl -6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and -CN,
  • R is selected from: fluoro, chloro, bromo, iodo,
  • R is selected from: fluoro, chloro, bromo, iodo,
  • X is selected from: carbon and nitrogen.
  • X is nitrogen .
  • X is carbon .
  • Y is independently selected from: hydrogen and CH3.
  • Y is absent or CH3.
  • Y hydrogen .
  • Y is absent.
  • Z is NH or O.
  • Z is NH.
  • Z is O.
  • a is 0 or 1 .
  • Suitably in the compounds of Formula (I), a is 0.
  • R is selected from: O, NH, CH2 and C1 alkyl substituted by halogen.
  • R is selected from:
  • R a benzoisothiazolyl substituted from 1 to 3 times by R a ; where each R a is independently selected from:
  • R 2 is selected from: O and S, suitably O.
  • R 3 is selected from:
  • each R b is independently selected from: -C(OH)(CH3)2, -CH2CH2CH2CH3, -CH3,
  • each R f is independently selected from:
  • X 1 is selected from: carbon and nitrogen;
  • Y 0 is selected from: hydrogen and CH3; Y is absent or CH3;
  • Z is NH or O
  • a 1 is 0 or 1 ;
  • R 0 is selected from: O, NH, CH2 and Ci alkyl substituted by halogen;
  • R is selected from:
  • R 2 is selected from: O and S;
  • R 3 is selected from:
  • R' independently selected from:
  • Cl -4alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, chloro, bromo, iodo, Cl -4alkyloxy, -OH, oxo, and -COOH,
  • -OCl -6alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, chloro, bromo, iodo, Cl -4alkyloxy, -OH, oxo, and -COOH, and -C(0)OCl -3alkyl; independently selected from:
  • R is selected from aryl, heteroaryl, cycloalkyl, heterocycloalkyl, -OCl -6alkyl, -OCl -6alkyl substituted with from 1 to 6 substituents independently selected from:
  • each R is independently selected from:
  • R is selected from aryl, heteroaryl, cycloalkyi, heterocycloalkyi, Cl -6alkyl, and Cl -6alkyl substituted with from 1 to 6 substituents independently selected from:
  • R and R are each independently selected from: aryl, heteroaryl, cycloalkyi, heterocycloalkyi, Cl -6alkyl, and
  • Cl -6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, -OH, and -COOH, nitro, and
  • each R is independently selected from: Cl -6alkyl substituted with from 1 to 9 substituents independently selected from:
  • R is selected from aryl, heteroaryl, cycloalkyl, heterocycloalkyl, cyano, Cl -3alkyl, and Cl -3alkyl substituted with from 1 to 4 substituents independently selected from: fluoro, oxo, -OH, -COOH, -OCl -5alkyl, -OCl -5alkyl substituted from 1 to 4 times by fluoro,
  • R and R are each independently selected from: aryl, heteroaryl, cycloalkyl, heterocycloalkyl,
  • Cl -6alkyl and Cl -6alkyl substituted with from 1 to 6 substituents independently selected from: fluoro, oxo, and -OH,
  • R is selected from: fluoro, chloro, bromo, iodo,
  • R is selected from: fluoro, chloro, bromo, iodo,
  • substituents independently selected from: fluoro, oxo, -OH, -COOH, -NH2, and -CN, and -OCl -5alkyl; or a pharmaceutically acceptable salt thereof.
  • X is selected from: carbon and
  • Y is independently selected from: hydrogen and CH3.
  • Y is absent or CH3.
  • Y is absent.
  • Z is NH or O.
  • Z is NH.
  • Z is O.
  • a is 0 or 1 .
  • Formula (II), a is 0.
  • a is 1 .
  • R is selected from: O, NH, CH2 and
  • R is selected from:
  • each R is independently selected from: fluoro
  • R is selected from: O and S, suitably O.
  • R is selected from:
  • each R is independently selected from: -C(OH)(CH3)2, -CH2CH2CH2CH3,
  • each R is independently selected from:
  • X 2 is selected from: carbon and nitrogen;
  • Y 20 is selected from: hydrogen and CH3;
  • Y 2 is absent or CH3;
  • Z 2 is NH or O
  • a 2 is 0 or 1 ;
  • R 20 is selected from: O, NH, CH2 and Ci alkyl substituted by halogen;
  • R 21 is selected from: aryl
  • aryl substituted from 1 to 3 times by R , bicycloheteroaryl, and
  • R is selected from: O and S;
  • R 23 is selected from:
  • heteroaryl substituted from 1 to 3 times by R ⁇ bicycloheteroaryl
  • each R is independently selected from:
  • -OCl-4alkyl substituted 1 to 4 times by fluoro; independently selected from:
  • R is selected from heteroaryl
  • substituents independently selected from: fluoro, oxo, -OH, -OCl -6alkyl, -NH2, and -NHcycloalkyl, heteroaryl,
  • each R is independently selected from:
  • R is selected from Cl-4alkyl, and Cl-4alkyl substituted by -OCl-6alkyl,
  • R and R are each independently selected from: Cl-4alkyl, and Cl-6alkyl substituted 1 to 4 times by fluoro, and cyano; and e2
  • each R is independently selected from:
  • R is selected from cyano, Cl-3alkyl, and Cl-3alkyl by -OCl-5alkyl
  • R and R are each independently selected from: Cl -4alkyl
  • X is selected from: carbon and
  • Y is independently selected from: hydrogen and CH3.
  • Y 2 is absent or CH3.
  • Y is absent.
  • Z is NH or O.
  • Z is NH.
  • Z is O.
  • a is 0 or 1 .
  • a is 0 or 1 .
  • Formula (III), a is 0.
  • a is 1 .
  • R is selected from: O, NH, CH2 and C1 alkyl substituted by halogen.
  • R is selected from: phenyl
  • each R a ⁇ is independently selected from:
  • R is selected from: O and S, suitably O.
  • R is selected from:
  • each R is independently selected from:
  • X 3 is selected from: carbon and nitrogen;
  • Y 30 is selected from: hydrogen and CH3; Y 3 is absent or CH3;
  • Z 3 is NH or O
  • a 3 is 0 or 1 ;
  • R 30 is selected from: O, NH, CH2 and Ci alkyl substituted by halogen;
  • R 31 is selected from:
  • R 32 is selected from: O and S;
  • R is selected from:
  • each R is independently selected from:
  • each R b3 is independently selected from: -C(OH)(CH3)2, -CH2CH2CH2CH3, -CH3, -OH
  • R f3 thiophenyl substituted 1 or 2 times by R ; and is independently selected from:
  • X is selected from: carbon and nitrogen.
  • X 3 is nitrogen.
  • X 3 is carbon.
  • Y is independently selected from: hydrogen and CH3.
  • Y 3 is absent or CH3.
  • Y is absent.
  • Z is NH or O.
  • Z 3 is NH.
  • Z 3 is O.
  • a is 0 or 1 .
  • a 3 is 0.
  • a 3 is 1 .
  • R is selected from: O, NH, CH2 and
  • R 3 is selected from:
  • each R is independently selected from:
  • R is selected from: O and S, suitably O.
  • R is selected from:
  • each R b3 is independently selected from: -C(OH)(CH3)2,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PCT/IB2017/056320 2016-10-13 2017-10-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors Ceased WO2018069863A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
JOP/2019/0072A JOP20190072A1 (ar) 2016-10-13 2017-06-16 مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
BR112019007609A BR112019007609A2 (pt) 2016-10-13 2017-10-12 ciclobutano 1,3 di-substituído ou derivados de azetidina como inibidores de sintase de prostaglandina d hematopoiética
CN201780075127.1A CN110072857A (zh) 2016-10-13 2017-10-12 作为造血前列腺素d合酶抑制剂的1,3-二取代的环丁酮或氮杂环丁烷衍生物
EA201990904A EA201990904A1 (ru) 2016-10-13 2017-10-12 1,3-дизамещенные производные циклобутана или азетидина в качестве ингибиторов гемопоэтической простагландин-d-синтазы
MX2019004320A MX2019004320A (es) 2016-10-13 2017-10-12 Derivados de azetidina o ciclobutano 1,3 di-sustituido como inhibidores de prostaglandina d sintasa hematopoyetica.
CR20190174A CR20190174A (es) 2016-10-13 2017-10-12 Deribados de azetidina o de ciclobutano 1,3-disustituido útiles como inhibidores de la prostaglandina d sistanasa hematopoiética (h-pgds)
EP17797738.6A EP3526206A1 (en) 2016-10-13 2017-10-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
US16/341,113 US11053234B2 (en) 2016-10-13 2017-10-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
JP2019520150A JP6938628B2 (ja) 2016-10-13 2017-10-12 造血器型プロスタグランジンｄシンターゼ阻害剤としての１，３二置換シクロブタンまたはアゼチジン誘導体
AU2017342156A AU2017342156B2 (en) 2016-10-13 2017-10-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
CA3038756A CA3038756A1 (en) 2016-10-13 2017-10-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
KR1020197013195A KR20190072565A (ko) 2016-10-13 2017-10-12 조혈 프로스타글란딘 d 신타제 억제제로서의 1,3 이치환된 시클로부탄 또는 아제티딘 유도체
IL265597A IL265597A (en) 2016-10-13 2019-03-25 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
ZA2019/01848A ZA201901848B (en) 2016-10-13 2019-03-26 1,3 di¿substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors
CONC2019/0003482A CO2019003482A2 (es) 2016-10-13 2019-04-08 Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética
PH12019500811A PH12019500811A1 (en) 2016-10-13 2019-04-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662407634P 2016-10-13 2016-10-13
US62/407,634 2016-10-13

Publications (1)

Publication Number Publication Date
WO2018069863A1 true WO2018069863A1 (en) 2018-04-19

Family

ID=60320926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2017/056320 Ceased WO2018069863A1 (en) 2016-10-13 2017-10-12 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors

Country Status (24)

Country Link
US (1) US11053234B2 (https=)
EP (1) EP3526206A1 (https=)
JP (1) JP6938628B2 (https=)
KR (1) KR20190072565A (https=)
CN (1) CN110072857A (https=)
AR (1) AR109931A1 (https=)
AU (1) AU2017342156B2 (https=)
BR (1) BR112019007609A2 (https=)
CA (1) CA3038756A1 (https=)
CL (1) CL2019000986A1 (https=)
CO (1) CO2019003482A2 (https=)
CR (1) CR20190174A (https=)
DO (1) DOP2019000087A (https=)
EA (1) EA201990904A1 (https=)
IL (1) IL265597A (https=)
JO (1) JOP20190072A1 (https=)
MA (1) MA46531A (https=)
MX (1) MX2019004320A (https=)
PE (1) PE20191020A1 (https=)
PH (1) PH12019500811A1 (https=)
TW (1) TW201827412A (https=)
UY (1) UY37440A (https=)
WO (1) WO2018069863A1 (https=)
ZA (1) ZA201901848B (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种氨基噻唑类化合物的合成方法
US11053234B2 (en) 2016-10-13 2021-07-06 Glaxosmithkline Intellectual Property Development Limited 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
WO2021256569A1 (ja) 2020-06-19 2021-12-23 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
WO2023113023A1 (ja) 2021-12-17 2023-06-22 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害するアザインドール誘導体
US11851440B2 (en) 2017-08-09 2023-12-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2B, compositions and methods
US11958840B2 (en) 2019-02-13 2024-04-16 Denali Therapeutics Inc. Compounds, compositions and methods
WO2024182556A1 (en) * 2023-02-28 2024-09-06 Reglagene, Inc. Compositions and methods for making and using small molecules for the treatment of health conditions
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
US12139478B2 (en) 2017-09-01 2024-11-12 Denali Therapeutics Inc. Compounds, compositions and methods
US12404242B2 (en) 2021-12-17 2025-09-02 Reglagene, Inc. Compositions and methods for making and using small molecules in the treatment of cancer

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3638672A1 (en) * 2017-06-13 2020-04-22 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as h-pgds inhibitors
CN113582880B (zh) * 2020-04-30 2023-11-17 南京药石科技股份有限公司 一种（3-氨基二环[1.1.1]戊烷-1-基）氨基甲酸叔丁酯的制备方法
CA3179059A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
CN111549000B (zh) * 2020-06-18 2022-07-29 中国医学科学院整形外科医院 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用
CN114085167A (zh) * 2021-12-13 2022-02-25 华中药业股份有限公司 一种杂质ts-3a的制备方法
US20250250265A1 (en) * 2022-04-15 2025-08-07 Vanderbilt University Benzothiazole-phenylsulfonyl-piperidine analogs as activators of nacylphosphatidylethanolamine hydrolyzing phospholipase d

Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031221A (en) * 1974-06-17 1977-06-21 American Hoechst Corporation Method of treating pain and hypertension
WO1999037614A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for the treatment of cns disorders
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
WO2005105779A1 (en) * 2004-04-28 2005-11-10 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2006077496A1 (en) * 2005-01-20 2006-07-27 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2007007778A1 (ja) 2005-07-13 2007-01-18 Taiho Pharmaceutical Co., Ltd. プロスタグランジンｄ合成酵素を阻害するベンゾイミダゾール化合物
WO2007007057A1 (en) * 2005-07-07 2007-01-18 Vernalis (R & D) Limited Antagonists of sns sodium channels
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
WO2007041634A1 (en) 2005-10-04 2007-04-12 Aventis Pharmaceuticals Inc. Pyrimidine amide compounds as pgds inhibitors
WO2007106705A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
US20080146569A1 (en) 2006-12-19 2008-06-19 Blake Tanisha D Nicotinamide Derivatives
WO2008121670A1 (en) 2007-03-30 2008-10-09 Sanofi-Aventis Pyrimidine hydrazide compounds as pgds inhibitors
WO2008122787A1 (en) 2007-04-05 2008-10-16 Evotec Ag Piperazine compounds for the inhibition of haematopoietic prostaglandin d synthase
WO2009109743A1 (en) * 2008-03-04 2009-09-11 Vernalis (R&D) Ltd. Azetidine derivatives
WO2009153721A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2010033977A2 (en) 2008-09-22 2010-03-25 Cayman Chemical Company Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2010104024A1 (ja) 2009-03-09 2010-09-16 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペラジン化合物
WO2011043359A1 (ja) 2009-10-06 2011-04-14 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
WO2011044307A1 (en) 2009-10-08 2011-04-14 Sanofi-Aventis Phenyloxadiazole derivatives as pgds inhibitors
WO2011090062A1 (ja) 2010-01-22 2011-07-28 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
WO2011143495A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2011143366A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
WO2012009649A1 (en) * 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012035023A1 (en) * 2010-09-13 2012-03-22 Novartis Ag Triazine-oxadiazoles
WO2012142498A2 (en) * 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
WO2013074387A1 (en) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
US20150038483A1 (en) * 2012-03-27 2015-02-05 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having trpv4-inhibiting activity
EP2857404A1 (en) * 2012-06-04 2015-04-08 Daiichi Sankyo Co., Ltd. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
WO2016156816A1 (en) * 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956359A (en) 1985-02-28 1990-09-11 A. H. Robins Company, Inc. 3-aryloxy and 3-arylthioazetidinecarboxamides as anticonvulsants and antiepileptics
IE58943B1 (en) 1985-02-28 1993-12-01 Robins Co Inc A H 3-Aryloxy-azetidine-carboxamides
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
GB9917385D0 (en) 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-I
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2007522233A (ja) * 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
WO2007003961A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US20070208426A1 (en) * 2006-03-03 2007-09-06 Sdgi Holdings, Inc. Spinal implant with improved surface properties for delivery
US20110172230A1 (en) 2006-08-23 2011-07-14 Takahiro Ishii Urea compound or salt thereof
WO2010024903A1 (en) * 2008-08-29 2010-03-04 Yangbo Feng BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
KR101400192B1 (ko) 2010-12-31 2014-05-27 제일모직 주식회사 포지티브형 감광성 수지 조성물, 이를 사용하여 제조된 감광성 수지막 및 상기 감광성 수지막을 포함하는 반도체 소자
CN103702961A (zh) 2011-05-23 2014-04-02 赛诺菲 含有n-烷基的氘代化合物的制备方法
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
ES2842592T3 (es) 2014-05-19 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
CN108430992A (zh) 2015-12-17 2018-08-21 阿斯特克斯医疗公司 作为h-pgds抑制剂的喹啉-3-甲酰胺
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم

Patent Citations (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031221A (en) * 1974-06-17 1977-06-21 American Hoechst Corporation Method of treating pain and hypertension
WO1999037614A1 (en) * 1998-01-23 1999-07-29 Vernalis Research Limited Azetidinecarboxamide derivatives for the treatment of cns disorders
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
WO2005094805A1 (ja) 2004-04-01 2005-10-13 Institute Of Medicinal Molecular Design. Inc. イミン誘導体及びアミド誘導体
WO2005105779A1 (en) * 2004-04-28 2005-11-10 Pfizer Limited 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2006077496A1 (en) * 2005-01-20 2006-07-27 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
WO2007007057A1 (en) * 2005-07-07 2007-01-18 Vernalis (R & D) Limited Antagonists of sns sodium channels
WO2007007778A1 (ja) 2005-07-13 2007-01-18 Taiho Pharmaceutical Co., Ltd. プロスタグランジンｄ合成酵素を阻害するベンゾイミダゾール化合物
JP2007051121A (ja) 2005-07-22 2007-03-01 Taiho Yakuhin Kogyo Kk プロスタグランジンｄ合成酵素を阻害するピリミジン化合物
WO2007041634A1 (en) 2005-10-04 2007-04-12 Aventis Pharmaceuticals Inc. Pyrimidine amide compounds as pgds inhibitors
WO2007106705A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
US20080146569A1 (en) 2006-12-19 2008-06-19 Blake Tanisha D Nicotinamide Derivatives
WO2008121670A1 (en) 2007-03-30 2008-10-09 Sanofi-Aventis Pyrimidine hydrazide compounds as pgds inhibitors
WO2008122787A1 (en) 2007-04-05 2008-10-16 Evotec Ag Piperazine compounds for the inhibition of haematopoietic prostaglandin d synthase
WO2009109743A1 (en) * 2008-03-04 2009-09-11 Vernalis (R&D) Ltd. Azetidine derivatives
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2009153721A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
WO2010033977A2 (en) 2008-09-22 2010-03-25 Cayman Chemical Company Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2407466A1 (en) * 2009-03-09 2012-01-18 Taiho Pharmaceutical Co., Ltd. Piperazine compound capable of inhibiting prostaglandin d synthase
WO2010104024A1 (ja) 2009-03-09 2010-09-16 大鵬薬品工業株式会社 プロスタグランジンd合成酵素を阻害するピペラジン化合物
WO2011043359A1 (ja) 2009-10-06 2011-04-14 協和発酵キリン株式会社 芳香族複素環化合物を含有する医薬
WO2011044307A1 (en) 2009-10-08 2011-04-14 Sanofi-Aventis Phenyloxadiazole derivatives as pgds inhibitors
WO2011090062A1 (ja) 2010-01-22 2011-07-28 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
WO2011143495A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
WO2011143366A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
WO2012009649A1 (en) * 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012035023A1 (en) * 2010-09-13 2012-03-22 Novartis Ag Triazine-oxadiazoles
WO2012142498A2 (en) * 2011-04-13 2012-10-18 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
WO2013074387A1 (en) * 2011-11-14 2013-05-23 Merck Sharp & Dohme Corp. Imidazole derivatives
US20150038483A1 (en) * 2012-03-27 2015-02-05 Shionogi & Co., Ltd. Aromatic 5-membered heterocyclic derivative having trpv4-inhibiting activity
EP2857404A1 (en) * 2012-06-04 2015-04-08 Daiichi Sankyo Co., Ltd. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR
WO2016156816A1 (en) * 2015-03-30 2016-10-06 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
ABE ET AL.: "Molecular cloning, chromosome mapping and characterization of the mouse CRTH2 gene, a putative member of the leukocyte chemo-attractant receptor family", GENE, vol. 227, 1999, pages 71 - 77
BOIE ET AL.: "Molecular cloning and characterization of the human prostanoid DP receptor", J. BIOL. CHEM., vol. 270, 1995, pages 18910 - 18916, XP002230274, DOI: doi:10.1074/jbc.270.32.18910
BROWN A ET AL: "Triazole oxytocin antagonists: Identification of an aryloxyazetidine replacement for a biaryl substituent", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 2, 15 January 2010 (2010-01-15), pages 516 - 520, XP026812522, ISSN: 0960-894X, [retrieved on 20091123] *
CARRON ET AL.: "Discovery of an Oral Potent Selective Inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS", ACS MED. CHEM. LETT., vol. 1, 2010, pages 59 - 63
CHRIST ET AL.: "Development and Characterization of New Inhibitors of the Human and Mouse Hematopoietic Prostaglandin D Synthases", J. MED. CHEM., vol. 53, 2010, pages 5536 - 5548, XP055002058, DOI: doi:10.1021/jm100194a
HOHWY ET AL.: "Novel Prostaglandin D Synthase Inhibitors Generated by Fragment-Based Drug Design", J. MED. CHEM., vol. 51, 2008, pages 2178 - 2186, XP008145992, DOI: doi:10.1021/jm701509k
IKUKO ET AL.: "Hematopoietic prostaglandin D synthase and DPi receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease", J. NEUROPATH. EXP. NEUR., vol. 66, 2007, pages 469 - 480
JEVGENIJA LUGININA ET AL.: "Ring-opening of carbamate-protected aziridines and azetidines in liquid sulfur dioxide", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY., vol. 9, 4 March 2016 (2016-03-04), DEWILEY-VCH, WEINHEIM., pages 1760 - 1771, XP002778813, ISSN: 1434-193X *
LEWIS ET AL.: "Prostaglandin D generation after activation of rat and human mast cells with anti-lgE", J. IMMUNOL., vol. 129, 1982, pages 1627 - 1631
MOHRI ET AL.: "Inhibition of prostaglandin D synthase suppresses muscular necrosis", AM. J. PATHOL., vol. 174, 2009, pages 1735 - 1744, XP008166859, DOI: doi:10.2353/ajpath.2009.080709
MOHRI ET AL.: "Prostaglandin D -mediated microglia/astrocyte interaction enhances astrogliosis and demyelination in twitcher", J. NEUROSCI., vol. 26, 2006, pages 4383 - 4393
NAKAGAWA ET AL.: "A prostaglandin D metabolite is elevated in the urine of Duchenne muscular dystrophy patients and increases further from 8 years old", CLINICA CHIMICA ACTA, vol. 423, 2013, pages 10 - 14
OKINAGA ET AL.: "Induction of hematopoietic prostaglandin D synthase in hyalinated necrotic muscle fibers: its implication in grouped necrosis", ACTA NEUROPATHOLOGICA, vol. 104, 2002, pages 377 - 84, XP008166878, DOI: doi:10.1007/s00401-002-0567-z
PAPALIODIS ET AL.: "Niacin-induced ''flush'' involves release of prostaglandin D from mast cells and serotonin from platelets: Evidence from human cells in vitro and an animal model", JPET, vol. 327, 2008, pages 665 - 672
REDENSEK ET AL.: "Expression and detrimental role of hematopoietic prostaglandin D synthase in spinal cord contusion injury", GLIA, vol. 59, 2011, pages 603 - 614
T. GREENE; P. WUTS: "Protecting Groups in Organic Synthesis", 2006, JOHN WILEY & SONS
TANAKA ET AL.: "Mast cells function as an alternative modulator of adipogenesis through 15-deoxy-delta-12, 14-prostaglandin J", AM. J. PHYSIOL. CELL PHYSIOL., vol. 301, 2011, pages C1360 - C1367
TURNER; BADYLACK, CELL TISSUE RES., vol. 347, no. 3, 2012, pages 759 - 74
URADE ET AL.: "Prostaglandin D synthase structure and function", VITAMINS AND HORMONES, vol. 58, 2000, pages 89 - 120
WEBER ET AL.: "Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D synthase", EUR. J. MED. CHEM., vol. 45, 2010, pages 447 - 454, XP026835666

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053234B2 (en) 2016-10-13 2021-07-06 Glaxosmithkline Intellectual Property Development Limited 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
US11851440B2 (en) 2017-08-09 2023-12-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2B, compositions and methods
US12139478B2 (en) 2017-09-01 2024-11-12 Denali Therapeutics Inc. Compounds, compositions and methods
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
US11958840B2 (en) 2019-02-13 2024-04-16 Denali Therapeutics Inc. Compounds, compositions and methods
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
CN111574473A (zh) * 2020-06-04 2020-08-25 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种氨基噻唑类化合物的合成方法
WO2021256569A1 (ja) 2020-06-19 2021-12-23 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害する縮環化合物
KR20230027059A (ko) 2020-06-19 2023-02-27 사토 세이야쿠 가부시키가이샤 H－pgds를 저해하는 축환 화합물
WO2023113023A1 (ja) 2021-12-17 2023-06-22 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害するアザインドール誘導体
KR20240121786A (ko) 2021-12-17 2024-08-09 사토 세이야쿠 가부시키가이샤 H－pgds를 저해하는 아자인돌 유도체
US12404242B2 (en) 2021-12-17 2025-09-02 Reglagene, Inc. Compositions and methods for making and using small molecules in the treatment of cancer
WO2024182556A1 (en) * 2023-02-28 2024-09-06 Reglagene, Inc. Compositions and methods for making and using small molecules for the treatment of health conditions
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions

Also Published As

Publication number Publication date
EA201990904A1 (ru) 2019-08-30
ZA201901848B (en) 2021-01-27
CL2019000986A1 (es) 2019-06-21
CA3038756A1 (en) 2018-04-19
MA46531A (fr) 2019-08-21
KR20190072565A (ko) 2019-06-25
PH12019500811A1 (en) 2020-01-20
PE20191020A1 (es) 2019-07-18
UY37440A (es) 2018-04-30
IL265597A (en) 2019-05-30
JOP20190072A1 (ar) 2019-04-07
AR109931A1 (es) 2019-02-06
JP6938628B2 (ja) 2021-09-22
AU2017342156B2 (en) 2020-10-22
DOP2019000087A (es) 2019-06-16
US11053234B2 (en) 2021-07-06
BR112019007609A2 (pt) 2019-07-02
JP2019536757A (ja) 2019-12-19
TW201827412A (zh) 2018-08-01
EP3526206A1 (en) 2019-08-21
AU2017342156A1 (en) 2019-04-18
US20190241554A1 (en) 2019-08-08
CR20190174A (es) 2019-08-21
CO2019003482A2 (es) 2019-04-12
CN110072857A (zh) 2019-07-30
MX2019004320A (es) 2019-06-12

Similar Documents

Publication Publication Date Title
US11053234B2 (en) 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin D synthase inhibitors
AU2016370779B2 (en) Quinoline-3-carboxamides as H-PGDS inhibitors
JP7577655B2 (ja) 環状尿素
AU2012328561A1 (en) Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
WO2019086141A1 (en) Novel, highly active amino-thiazole substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
KR20220004726A (ko) Jak 억제제로서의 치환된 피롤로피리딘
CA2778174A1 (en) Tricyclic pyrazol amine derivatives as pi3k inhibitors
CN101472902A (zh) 新哌嗪化合物及其作为hcv聚合酶抑制剂的用途
IL279482B2 (en) Thiophene derivatives for the treatment of disorders caused by ige
AU2018326734B2 (en) Substituted 2-azabicyclo(3.1.1)heptane and 2-azabicyclo(3.2.1)octane derivatives as orexin receptor antagonists
JP2025520511A (ja) キナーゼモジュレーターおよびその使用方法
WO2018229629A1 (en) Chemical compounds as h-pgds inhibitors
TW201321384A (zh) 作為鈣通道阻斷劑之經取代之八氫吡咯并［１，２－ａ］吡□磺醯胺
US20210139507A1 (en) Fused pyridines which act as inhibitors of h pgds
US20220009918A1 (en) Chemical Compounds
CN113072546B (zh) 五元杂芳衍生物及其制备方法和用途
BR112021014539A2 (pt) Composto, ativador sirt6, composição farmacêutica, método para tratar e/ou prevenir uma doença inflamatória periférica e uso do composto
WO2011016576A1 (en) Alanine derivatives as inhibitors of apoptosis proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17797738

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3038756

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: NC2019/0003482

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2019520150

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: NC2019/0003482

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017342156

Country of ref document: AU

Date of ref document: 20171012

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112019007609

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: DZP2019000224

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20197013195

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017797738

Country of ref document: EP

Effective date: 20190513

ENP Entry into the national phase

Ref document number: 112019007609

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20190415

WWG Wipo information: grant in national office

Ref document number: NC2019/0003482

Country of ref document: CO